Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The FHS cohort supported these results: The rs7903146 T allele was significantly associated with lower estimated GFR (P = 0.01) and higher cystatin C (P = 0.004) in adjusted analyses overall and among those without diabetes.
|
18650481 |
2008 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
During a median of 65.5 mo follow-up, carriers of T allelic variants in exons 21 or 26 had a three-fold risk for delayed graft function (DGF), a trend to slower recovery of renal function and lower GFR at study end, and significantly higher incidences of new-onset diabetes and cytomegalovirus reactivation compared with carriers of the wild-type genotype.
|
19470683 |
2009 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Considering baseline GFR, age at enrolment and diabetes duration as confounders, Cox regression analysis identified 894GT genotype as a risk factor for DN progression (HR = 1.843 [95% CI 1.088 - 3.119], P = 0.023) and 894TT genotype as a risk factor for major cardiovascular event (HR = 2.515 [95% CI 1.060 - 5.965], P = 0.036).
|
24603156 |
2013 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
After multivariable logistic regression analysis, younger age (odds ratio (OR) 0.023 per decade, 95% confidence interval (CI) 0.00065 to 0.455; <i>p</i> = 0.012), presence of diabetes (OR 11.40, 95 CI 2.82 to 61.55; <i>p</i> = 0.0003), and measured GFR (OR 0.052 per mL/min decrease; 95% CI 0.0025 to 0.66) were associated with hyperphosphatemia.
|
28218647 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although intensive glycemic management has been shown to delay the onset and progression of increased urinary albumin excretion and reduced GFR in patients with diabetes, conservative dose selection and adjustment of antihyperglycemic medications are necessary to balance glycemic control with safety.
|
28465376 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neither GFR nor renal blood flow were affected by diabetes or chronic renal denervation alone.
|
27727024 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since albuminuria is a strong risk factor for GFR loss, modifiable lifestyle factors that lead to an improvement in albuminuria would likely reduce the burden of CKD in high-risk individuals, such as patients with diabetes.
|
28287463 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined the incidence of diabetes in kidney donors, and compared GFR change over time in diabetic to nondiabetic donors, in addition to the effect of diabetes mellitus (DM) on the development of proteinuria, hypertension, and end-stage renal disease (ESRD).
|
28681494 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetes is strongly associated with both albuminuria and reduced GFR independent of demographics and hypertension, contributing substantially to the burden of CKD in the United States.
|
29054846 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The associations of soluble DPP-4 levels with serum creatinine and GFR remained significant after adjusting for age, body mass index, and duration of diabetes.
|
30302966 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
To address this issue, we analyzed GFR follow-up data on participants with type 1 diabetes undergoing <sup>125</sup>I-iothalamate clearance on entry into the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications study.
|
31123181 |
2019 |